Other: d5w (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
222 | Primary nephrotic syndrome | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02592798 (ClinicalTrials.gov) | March 1, 2016 | 29/10/2015 | Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) | A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease) | Nephrotic Syndrome;Focal Segmental Glomerulosclerosis;Minimal Change Disease | Drug: Abatacept;Other: Normal Saline;Other: D5W | Bristol-Myers Squibb | NULL | Completed | 6 Years | N/A | All | 36 | Phase 2 | United States |